ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
61.4%+3.2 pts over 5 years
Operating margin
12.6%+20.3 pts over 5 years
Net margin
8.9%+19.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +43.8% | +40.8% | +33.5% | +27.7% | |
| Gross profit | +48.8% | +45.1% | +34.9% | +23.9% | |
| Operating income | +18922.8% | – | – | +13.0% | |
| Net income | – | – | – | +17.7% | |
| EPS, diluted | – | – | – | +9.7% | |
| Free cash flow | +258.7% | – | +79.8% | +27.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 2.4% | -11.0% | 16.6% | |
| Return on assets | 1.3% | -4.9% | 5.7% | |
| Current ratio | 3.22 | 2.17 | 2.71 | |
| Debt to equity | 0.00 | 0.95 | 0.57 | |
| Net debt to EBITDA | -0.65× | 6.21× | 0.12× | |
| Interest coverage | 1.8× | -1.7× | 3.4× | |
| Inventory turnover | 2.5× | 1.6× | 2.4× | |
| Capex to revenue | 3.5% | 2.9% | 1.6% | |
| Diluted shares | 12M | 12M | 21M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ani Pharmaceuticals generated $402.73M from operations and spent $87.60M on capital expenditure, dividends and share buybacks. 58% of that went back into the business.
Generated
$402.73M
Used
$87.60M
Capital expenditure$50.37M58%Dividends$6.22M7%Share buybacks$31.00M35%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.9%
×Asset turnover0.65×
×Equity multiplier2.89×
=Return on equity, FY202516.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.9% | 0.65× | 2.89× | 16.6% |
| FY2024 | -3.0% | 0.56× | 2.62× | -4.4% |
| FY2023 | 3.9% | 0.58× | 2.23× | 5.0% |
| FY2022 | -15.1% | 0.41× | 2.37× | -14.8% |
| FY2021 | -19.7% | 0.35× | 2.33× | -16.1% |
| FY2020 | -10.8% | 0.45× | 2.25× | -11.0% |
| FY2019 | 3.0% | 0.47× | 2.16× | 3.0% |
| FY2018 | 7.7% | 0.48× | 2.27× | 8.3% |
| FY2017 | -0.6% | 0.48× | 2.13× | -0.6% |
| FY2016 | 3.1% | 0.42× | 1.84× | 2.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$78.34M
- Cash generatingOperating cash flow above zero$185.23M
- Return on assets improvedROA up on the prior year-2.0% → 6.1%
- Earnings backed by cashOperating cash flow above net income$185.23M vs $78.34M
- Less leverageLong-term debt to assets fell24.1% → 20.3%
- Better liquidityCurrent ratio rose2.72 → 2.71
- No dilutionShare count did not rise19M → 21M
- Gross margin improvedGross margin up on the prior year59.27% → 61.36%
- More efficientAsset turnover rose0.68 → 0.69